Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260802 | 0.85 | PGR (0.48) | TDP1PGRMAPTGPR35POLB | |
| SCHEMBL31108692 | 0.85 | PGR (0.48) | TDP1PGRMAPTGPR35POLB | |
| SCHEMBL9483715 | 0.78 | GPR35 (0.42) | KIF11NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL12559695 | 0.78 | POLB (0.42) | KIF11NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL256723 | 0.76 | MAPT (0.45) | TDP1MAPTGPR35KMT2A | |
| SCHEMBL8873079 | 0.75 | TDP1 (0.40) | NPC1TDP1MAPTGPR35POLB | |
| SCHEMBL3939120 | 0.74 | POLB (0.49) | TDP1MAPTGPR35POLBS100A4 | |
| SCHEMBL8129299 | 0.73 | CYP11B1 (0.53) | KIF11NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL7604948 | 0.73 | MAPT (0.47) | TDP1MAPTGPR35S100A4KMT2A | |
| SCHEMBL13545419 | 0.73 | BRD4 (0.49) | TDP1MAPTGPR35POLBS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | KIF11 3440/4885NPC1 2542/4885MAPK13 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.